Akari Therapeutics (NASDAQ:AKTX) Shares Break Above 200 Day Moving Average – Here’s Why

Akari Therapeutics PLC (NASDAQ:AKTX) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $9.14 and traded as high as $9.33. Akari Therapeutics shares last traded at $9.20, with a volume of 42,294 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Maxim Group raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Monday, July 20th. Wall Street Zen upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Alliance Global Partners upgraded Akari Therapeutics to a “strong-buy” rating in a research report on Friday, September 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Akari Therapeutics in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.33.

Akari Therapeutics Stock Performance

The stock’s fifty day moving average is $9.30 and its 200-day moving average is $9.11.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research centers on complement-system and leukotriene biology, which are involved in immune responses and inflammation.

Its lead investigational product is nomacopan, a recombinant protein designed to inhibit complement component C5 and leukotriene B4. Akari is also developing PAS-nomacopan, a longer-acting version intended to extend the therapy’s duration of action.